<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The ability to tailor biologic therapy based on the status of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biomarkers and monoclonal antibodies has become very important in the last years </plain></SENT>
<SENT sid="1" pm="."><plain>The role of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biomarkers in treating <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, specifically the K-<z:mp ids='MP_0011356'>RAS</z:mp> gene, was identified </plain></SENT>
<SENT sid="2" pm="."><plain>K-<z:mp ids='MP_0011356'>RAS</z:mp> had a higher interest after Lievre and colleagues reported at the 2008 American Society of Clinical <z:hpo ids='HP_0002664'>Oncology</z:hpo> (ASCO) meeting, their analysis of K-<z:mp ids='MP_0011356'>RAS</z:mp> mutations in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from patients who did not appear to benefit from cetuximab therapy, providing additional data involving K-<z:mp ids='MP_0011356'>RAS</z:mp> mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and their lack of response to cetuximab, as part of first-line therapy for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, other trials evaluated the K-<z:mp ids='MP_0011356'>RAS</z:mp> status and the first-line treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, the treatment of refractory <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> and dual-antibody therapy in the first-line treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with mutant K-<z:mp ids='MP_0011356'>RAS</z:mp> <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> have no benefit from cetuximab, no matter the type of chemotherapy regimen </plain></SENT>
</text></document>